536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP

Performance

  • Low
  • ₹55
  • High
  • ₹57
  • 52 Week Low
  • ₹24
  • 52 Week High
  • ₹70
  • Open Price₹57
  • Previous Close₹55
  • Volume8,602
  • 50 DMA₹56.19
  • 100 DMA₹51.86
  • 200 DMA₹43.13

Investment Returns

  • Over 1 Month -3.45%
  • Over 3 Month + 21.23%
  • Over 6 Month + 30.87%
  • Over 1 Year + 137.89%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 104.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 101
  • P/B Ratio
  • 3.5
  • Average True Range
  • 3.13
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.79
  • RSI
  • 44.77
  • MFI
  • 21.43

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹57.45
+ 2.69 (4.91%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹56.48
  • 50 Day
  • ₹56.19
  • 100 Day
  • ₹51.86
  • 200 Day
  • ₹43.13

Resistance and Support

54.77 Pivot Speed
  • R3 54.86
  • R2 54.83
  • R1 54.80
  • S1 54.74
  • S2 54.71
  • S3 54.68

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 84.87 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 25% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 126 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results
2025-04-12 Others Inter-alia, to consider 1. Convening of an EGM for appointment of Non-Executive Independent Director of the Company. 2. To appoint a scrutinizer for the upcoming EGM. 3. Other business matters.

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

51.98%
42.69%
5.33%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹57 As on 23 January, 2026 | 11:58

The Market Cap of Novelix Pharmaceuticals is ₹101.2 Cr As on 23 January, 2026 | 11:58

The P/E ratio of Novelix Pharmaceuticals is 104.3 As on 23 January, 2026 | 11:58

The PB ratio of Novelix Pharmaceuticals is 3.5 As on 23 January, 2026 | 11:58

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23